Poster Viewing Sessions
More information will follow.
Four poster viewing sessions are organized during the 32nd Annual Meeting.7
More information about the schedule will follow soon.
Thursday, 21 November 2024
12:30 - 13:30 | Poster Viewing Session I | |
17:15 - 18:15 | Poster viewing II |
Friday, 22 November 2024
10:00 - 10:30 | Poster Viewing Session III | |
13:00 - 14:00 | Poster viewing IV |
During those sessions, our Young Investigators, ECF Fellows and Investigators will present their posters to the jury onsite. E-posters will be also available for consultation on the ECF website.
The winners of the 3 Young Investigators Awards (one Award per category) will be announced on Friday, 10 November 2023 from 17:20 - 17:30.
The winners will also present their posters during the Young Investigators Awards presentations which will be held on Saturday, 11 November 2023 from 10:30 - 11:00.
Hour Location |
Title | Location |
---|---|---|
12:30 - 13:30 |
Poster Viewing Session I - Clinical + Epidemiology |
|
-- |
ID 2: MACSiMiSE-BRAIN: a multi-centre randomised placebo controlled clinical trial Anna-Victoria De Keersmaecker |
|
-- |
ID 11: Assessing the risk of relapse after in vitro fertilization in women with MS Marie Mainguy |
|
-- |
ID 21: Social Outcomes as a Measure of Recovery in Patients with Early Onset MS Julian Lui |
|
-- |
ID 23: Teriflunomide adherence in multiple sclerosis Vincent van Pesch |
|
-- |
ID 30: Cognitive Correlates of Apathy in Multiple Sclerosis: an 8-year longitudinal study Mariachiara Gaita |
|
-- |
ID 31: Premature thymic involution in MS and other autoimmune diseases Wein-Na Jin |
|
-- |
ID 33: Does MSWS-12, patient-reported outcome of walking ability, mirror ataxic symptoms? Lina Anderhalten |
|
-- |
ID 35: A CASE OF TUMEFACTIVE MULTIPLE SCLEROSIS Sofia Ntymenou |
|
-- |
ID 36: RADIOLOGICALLY ISOLATED SYNDROME: A DIAGNOSTIC AND THERAPEUTIC CHALLENGE Sofia Ntymenou |
|
-- |
ID 37: Cancer risk in MS: a 10-year nationwide study Chloé Pierret |
|
-- |
ID 38: PRIMUS: Reusing research data as decision support for precision medicine in MS Stanislas Demuth |
|
-- |
ID 44: Phase 3 REMODEL I/II Trials: Efficacy, Safety & Tolerability of Remibrutinib in RMS Prof. Dr Xavier Montalban |
|
-- |
ID 47: Remibrutinib’s Safety Across Immune-Mediated Diseases Supports Development in MS Prof. Dr Xavier Montalban |
|
-- |
ID 54: TRACK-MS: A new test to detect cognitive impairment in different subtypes of MS Ms Daniela Taranu |
|
-- |
ID 60: Epidemiological Trends and Disease Burden of Multiple Sclerosis from 1990 to 2019 Sara Samadzadeh |
|
-- |
ID 61: MOGAD Patient Spectrum: Insights from a Turkish Single-Center Study Abdulkadir Tunç |
|
-- |
ID 62: Fenebrutinib in multiple sclerosis–results from the phase II FENopta study Prof. Dr Amit Bar-Or |
|
-- |
ID 65: Validation of protein-MS associations by Mendelian randomisation in a large cohort Shannon Bernard Healey |
|
-- |
ID 67: Late Onset Multiple Sclerosis, Clinical Characteristics of a Mexican Group Diana Gomez |
|
-- |
ID 69: Decoding cognitive dysfunction in multiple sclerosis: role of brainstem atrophy Eline Van Doninck |
|
-- |
ID 71: Progressive multiple sclerosis: identifying distinct cognitive-affective profiles Angela Boschetti |
|
17:15 - 18:15 |
Poster Viewing Session II - Treatment + Investigations Part 1 |
|
-- |
ID 10: Circadian rhythm and interferon safety in multiple sclerosis Dr Mehdi Maghbooli |
|
-- |
ID 15: Safety and Efficacy of Tolebrutinib in RMS Participants: 3-Year Results Dr Jiwon Oh |
|
-- |
ID 16: MRI Outcomes from the LTS Study of Tolebrutinib in RMS Participants: 3-Year Results Dr Jiwon Oh |
|
-- |
ID17: Real-life outcome of teriflunomide treatment and its predictors in RRMS patients Hongmei Tan |
|
-- |
ID 20: FATIGUE IS REDUCED DURING TREATMENT WITH DIMETHYL FUMARATE IN MULTIPLE SCLEROSIS Louise Moelgaard |
|
-- |
ID 26: Health-related effects in multiple sclerosis during functional training Charlotte Klump |
|
-- |
ID 27: Phase 3 trials of evobrutinib in relapsing MS: Design and baseline characteristics Prof. Dr Xavier Montalban |
|
-- |
ID28: Long term (5-year) efficacy and safety of evobrutinib in patients with relapsing MS Prof. Dr Xavier Montalban |
|
-- |
ID34: Effect of Evobrutinib on Vitality, Mental Health, and Fatigue in relapsing MS Prof. Dr Patrick Vermersch |
|
-- |
ID 40: Patient preference and real-world outcomes of diroximel fumarate therapy in RRMS Angela Guerra |
|
-- |
ID 41: SISTER – Subcutaneous: Observational study on TYSABRI® Patient Preference Angela Guerra |
|
-- |
ID 42: Remibrutinib Ameliorates CNS Autoimmune Disease - Insights From EAE Virginia DeLasHeras |
|
-- |
ID 43: Remibrutinib Inhibits Neuroinflammation Driven by B cells and Myeloid Cells in EAE Virginia DeLasHeras |
Hour Location |
Title | Location |
---|---|---|
10:00 - 10:30 |
Poster Viewing Session III - Basic Studies |
|
-- |
ID 5: The immunometabolic landscape of bone marrow cells in multiple sclerosis Caiyun Qi |
|
-- |
ID 6: The influence of dopamine on the monocyte-induced Th17-immune response in MS Dr Mikhail Melnikov |
|
-- |
ID 7: IRAK-M suppresses microglial NLRP3 inflammasome activation and pyroptosis in EAE Bingtian Xu |
|
-- |
ID 8: Reduced Aβ amyloid deposits relate to inflammation & neuronal survival in MS cortex Dr Jonathan Pansieri |
|
-- |
ID 9: Myelopoiesis and its therapeutic implication in multiple sclerosis Kaibin Shi |
|
-- |
ID 12: Physiological & inflammation induced aging impairs human oligodendroglial function Ms Farina Windener |
|
-- |
ID 13: APOE Bearing Astrocytic Extracellular Vesicles Alleviates NMOSD Xindi Li |
|
-- |
ID 14: Connexin hemichannel blockade ameliorates EAE by suppressing glial inflammation Ezgi Ozdemir Takase |
|
-- |
ID 24: CSF CHIT1 predicts disability progression and reflects microglia activation in MS Stijn Swinnen |
|
-- |
ID 45: Halting Brain Inflammation and Degeneration by Antagonizing FPR1 Prof. Fu-Dong Shi |
|
-- |
ID 51: Immunoglobulin Deposition in the Progressive Multiple Sclerosis Spinal Cord Andrew Lockhart |
|
-- |
ID 53: Aberrant iron deposition in the MS spinal cord relates to neurodegeneration Dr Marco Pisa |
|
-- |
ID 58: Anodal tDCS promotes remyelination in the cuprizone model Ms Elena Rossi |
|
-- |
ID 59: Candidate MS progression associated genes in human stem cell-derived neural models Mollie McKeon |
|
-- |
ID 73: Transcorneal Electrical Stimulation modulates visual function in vivo Dr Valerio Castoldi |
|
13:00 - 14:00 |
Poster Viewing Session IV - Treatment + Investigations Part 2 |
|
-- |
ID 46: An evidence based Global MS Patient Charter created by a multi-stakeholder alliance Pauline Gieseler |
|
-- |
ID 48: Retrospective data analysis of a German cladribine cohort from MS treatment centres Michael Ernst |
|
-- |
ID 50: Evoked potentials to predict rehabilitation outcome in progressive MS Alessandro Gradassi |
|
-- |
ID 56: Extended interval dosing with ocrelizumab in multiple sclerosis Dr Frederik Novak Stenstad |
|
-- |
ID 57: Treatment switch from OFA to OCR in RMS: Two case reports Tanja Maler |
|
-- |
ID 63: Myelin PET imaging of cervical spinal cord is associated with disability in MS Milena Pitombeira |
|
-- |
ID 64: Lymphopenia in DMF: Are there characteristics that can predict its occurrence? Diana Gomez |
|
-- |
ID66: Vulnerability of thalamic nuclei at CSF interface during the entire course of MS Dr Ismail Koubiyr |
|
-- |
ID 68: Reference FLAIR lesion volumes for the follow up of MS patients Annemie Ribbens |
|
-- |
ID 70: EEG markers of cognitive involvement in MS: Event-Related Potentials to the SDMT Marta Tacchini |
|
-- |
ID 72: Remote digital Symbol-Digit Modalities Test in pwMS: Validity and Reliability Mr Michelangelo Dini |
|
13:00 - 14:00 |
Poster Viewing Session I - Clinical + Epidemiology |
|
-- |
ID 52: Longitudinal MRI structural and cognitive measures in MOGAD and MS Dr Valentina Camera |
|
17:20 - 17:30 |
Announcement Young Investigator Award Winners |
Hour Location |
Title | Location |
---|---|---|
10:30 - 11:00 |
Young Investigator Awards |